State of the Art: Newer biomarkers in heart failure (Q27027899)

Lori B. Daniels

series ordinal

2

1 reference

Alan S. Maisel

series ordinal

3

1 reference

language of work or name

1 reference

June 2015

1 reference

European Journal of Heart Failure

published in

1 reference

volume

17

1 reference

issue

6

1 reference

page(s)

559-69

1 reference

The role of natriuretic peptides: from the emergency department throughout hospitalization

cites work

1 reference

Emerging biomarkers in heart failure

21 January 2018

1 reference

Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay

21 January 2018

1 reference

Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure

21 January 2018

1 reference

The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure

21 January 2018

1 reference

Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells

21 January 2018

1 reference

Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction

21 January 2018

1 reference

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system

21 January 2018

1 reference

Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature

21 January 2018

1 reference

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study

21 January 2018

1 reference

Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients

21 January 2018

1 reference

Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction

21 January 2018

1 reference

Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure

21 January 2018

1 reference

Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy

21 January 2018

1 reference

Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure

21 January 2018

1 reference

High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure

21 January 2018

1 reference

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

21 January 2018

1 reference

Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure

21 January 2018

1 reference

Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure

21 January 2018

1 reference

Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study).

21 January 2018

1 reference

Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.

21 January 2018

1 reference

Interleukin receptor family member ST2 concentrations in patients following heart transplantation

21 January 2018

1 reference

Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study

21 January 2018

1 reference

Soluble ST2 predicts elevated SBP in the community

21 January 2018

1 reference

ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality

21 January 2018

1 reference

Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction

21 January 2018

1 reference

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

21 January 2018

1 reference

Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction

21 January 2018

1 reference

Galectin-3 and cardiac function in survivors of acute myocardial infarction.

21 January 2018

1 reference

Galectin-3: an open-ended story

21 January 2018

1 reference

The regulation of inflammation by galectin-3.

21 January 2018

1 reference

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

21 January 2018

1 reference

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis

21 January 2018

1 reference

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

21 January 2018

1 reference

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

21 January 2018

1 reference

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure

21 January 2018

1 reference

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials

21 January 2018

1 reference

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure

21 January 2018

1 reference

Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction

21 January 2018

1 reference

Galectin-3 in heart failure with preserved ejection fraction

21 January 2018

1 reference

Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.

21 January 2018

1 reference

Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

21 January 2018

1 reference

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

21 January 2018

1 reference

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

21 January 2018

1 reference

Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.

21 January 2018

1 reference

Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis

21 January 2018

1 reference

Elevated galectin-3 precedes the development of CKD

21 January 2018

1 reference

Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies

21 January 2018

1 reference

The fibrosis marker galectin-3 and outcome in the general population.

21 January 2018

1 reference

Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community

21 January 2018

1 reference

Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study

21 January 2018

1 reference

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

21 January 2018

1 reference

Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study

21 January 2018

1 reference

Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.

21 January 2018

1 reference

Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).

21 January 2018

1 reference

Galectin-3: a modifiable risk factor in heart failure

21 January 2018

1 reference

Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB.

21 January 2018

1 reference

A new season for cardiac troponin assays: it's time to keep a scorecard

21 January 2018

1 reference

Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure

21 January 2018

1 reference

Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section

21 January 2018

1 reference

Cardiac troponin and outcome in acute heart failure

21 January 2018

1 reference

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

21 January 2018

1 reference

Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction

21 January 2018

1 reference

Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure

21 January 2018

1 reference

Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials

21 January 2018

1 reference

Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study

21 January 2018

1 reference

Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.

21 January 2018

1 reference

Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study

21 January 2018

1 reference

Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population

21 January 2018

1 reference

Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population

21 January 2018

1 reference

High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort

21 January 2018

1 reference

Defining high-sensitivity cardiac troponin concentrations in the community.

21 January 2018

1 reference

Growth differentiation factor 15 in heart failure: an update

21 January 2018

1 reference

Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial

21 January 2018

1 reference

Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea

21 January 2018

1 reference

Effects of prehospital medications on mortality and length of stay in congestive heart failure

21 January 2018

1 reference

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

21 January 2018

1 reference

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.

21 January 2018

1 reference

Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial

21 January 2018

1 reference

Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial.

21 January 2018

1 reference

Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure

21 January 2018

1 reference

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial

21 January 2018

1 reference

Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study

21 January 2018

1 reference

Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome.

21 January 2018

1 reference

Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery

21 January 2018

1 reference

Breathing not properly 10 years later: what we have learned and what we still need to learn

21 January 2018

1 reference

Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure

21 January 2018

1 reference

Multi-marker strategies in heart failure: clinical and statistical approaches

21 January 2018

1 reference

A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme.

21 January 2018

1 reference

Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial

21 January 2018

1 reference

Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study.

21 January 2018

1 reference

Surfing the biomarker tsunami at JACC: heart failure

21 January 2018

1 reference

Analytical validation of a high-sensitivity cardiac troponin T assay

21 January 2018

1 reference

7 January 2021

Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods

1 reference

7 January 2021

Troponins and high-sensitivity troponins as markers of necrosis in CAD and heart failure

1 reference

7 January 2021

Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea

1 reference

7 January 2021

Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure

1 reference

7 January 2021

Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study

1 reference

7 January 2021

Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure

1 reference

7 January 2021

Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial

1 reference

7 January 2021

Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

1 reference

7 January 2021

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial

1 reference

7 January 2021

Galectin-3 in heart failure: high levels are associated with all-cause mortality

1 reference

7 January 2021

Cardiac troponin I as diagnostic and prognostic marker in severe heart failure

1 reference

7 January 2021

Prevalence and determinants of troponin T elevation in the general population

1 reference

7 January 2021

β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure

1 reference

7 January 2021

release_mn2chbxp5jc5ncmh6lpxqujshm

Identifiers

DOI

10.1002/EJHF.273

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mn2chbxp5jc5ncmh6lpxqujshm

24 November 2022